Pancreatic Cancer mRNA Vaccine Shows Lasting Results

Got story updates? Submit your updates here. ›

A 72-year-old Florida woman named Donna Gustafson traveled to Australia and experienced concerning symptoms, including jaundice, that led her to seek emergency medical care. After further testing, Gustafson was diagnosed with pancreatic cancer. She then enrolled in an early clinical trial for an experimental mRNA vaccine treatment, which has shown promising long-term results in combating the disease.

Why it matters

Pancreatic cancer is one of the deadliest forms of the disease, with a 5-year survival rate of only about 10%. New treatment approaches like this mRNA vaccine hold the potential to significantly improve outcomes for patients diagnosed with pancreatic cancer.

The details

Gustafson's jaundice and other symptoms led doctors to discover she had stage 3 pancreatic cancer. She then enrolled in an early-stage clinical trial for an experimental mRNA vaccine treatment. The vaccine is designed to train the immune system to recognize and attack pancreatic cancer cells. After receiving the vaccine, Gustafson has shown no signs of cancer progression for over 18 months, a promising result in a disease that typically has a very poor prognosis.

• Gustafson traveled from Florida to Australia in early 2026.
• Two days into her trip, Gustafson experienced jaundice and other concerning symptoms.
• Gustafson was diagnosed with stage 3 pancreatic cancer shortly after returning from her trip.
• Gustafson enrolled in the mRNA vaccine clinical trial in mid-2026.
• As of April 2026, Gustafson has shown no signs of cancer progression for over 18 months since receiving the experimental treatment.

What they’re saying

What’s next

Researchers will continue to monitor Gustafson's progress and enroll additional patients in the clinical trial to further evaluate the mRNA vaccine's long-term efficacy against pancreatic cancer.